Non-irradiated area of intraoperative radiotherapy with electron technique: outcomes and pattern of failure in early-stage breast cancer from a single-center, registry study

2024-9-10

Reply to the Letter to the editor “Does axillary lymph node recurrence breast cancer subtype information matter for prognosis estimation?”

2024-9-1

Hub metastatic gene signature and risk score of breast cancer patients with small tumor sizes using WGCNA

2024-8-27

Applying whole-genome and whole-exome sequencing in breast cancer: a review of the landscape

2024-8-27

Clinicopathological and prognostic features of HER2-null and HER2-low advanced breast cancer treated with eribulin or capecitabine

2024-8-14

Increasing survivors of anthracycline-related cardiomyopathy with breast cancer in trastuzumab era: thirty-one-year trends in a Japanese Community

2024-8-13

Trastuzumab deruxtecan for the treatment of patients with HER2-positive breast cancer with brain and/or leptomeningeal metastases: an updated overall survival analysis using data from a multicenter retrospective study (ROSET-BM)

2024-8-12

Targeted therapies in HER2-positive breast cancer with receptor-redirected Arazyme-linker-Herceptin as a novel fusion protein

2024-8-9

Survival in patients with rheumatoid arthritis and early breast cancer treated with tumor necrosis factor inhibitors

2024-8-8

Acute toxicity of hypofractionated radiotherapy for Japanese breast cancer patients after surgery: a single center prospective observational study (HyPORT-BC)

2024-8-8

Efficacy and safety of adjuvant therapies in older patients with breast cancer: a systematic review and meta-analysis of real-world data

2024-8-1

Uptake of ultra-hypofractionated radiation therapy following breast-conserving surgery among patients with early-stage breast cancer: a multi-institutional questionnaire survey

2024-7-24

Does axillary lymph node recurrence breast cancer subtype information matter for prognosis estimation?

2024-7-20

Identification and validation of screening models for breast cancer with 3 serum miRNAs in an 11,349 samples mixed cohort

2024-7-19

Case series of Li-Fraumeni syndrome: carcinogenic mechanisms in breast cancer with TP53 pathogenic variant carriers

2024-7-17

Development of a nomogram to predict recurrence scores obtained using Oncotype DX in Japanese patients with breast cancer

2024-7-17

Comparison of locoregional recurrence risk among nipple-sparing mastectomy, skin-sparing mastectomy, and simple mastectomy in patients with ductal carcinoma in situ: a single-center study

2024-7-17

High-risk pathogenic germline variants in blood relatives of BRCA1/2 negative probands

2024-7-13

Quality of life in women with breast cancer undergoing neoadjuvant chemotherapy: comparison between PICC and PICC-port

2024-7-9

The effect of exercise and educational programs for breast cancer patients on the development of breast cancer-related lymphoedema: secondary endpoint from a randomized controlled trial in the Setouchi Breast Project-10

2024-7-9

Breast-conserving surgery versus modified radical mastectomy in T1-2N3M0 stage breast cancer: a propensity score matching analysis

2024-7-8

Development and validation of a neoadjuvant chemotherapy pathological complete remission model based on Reg IV expression in breast cancer tissues: a clinical retrospective study

2024-7-8

Prognosis of isolated locoregional recurrence after early breast cancer with immediate breast reconstruction surgery: a retrospective multi‑institutional study

2024-6-19

Impact of immediate breast reconstruction on perioperative therapy: insights from a Japanese Nationwide Registry

2024-6-19

Exploration of treatment strategies and susceptibility gene of postoperative nausea and vomiting in breast cancer patients: a randomised controlled trial

2024-6-19

Trastuzumab deruxtecan versus treatment of physician’s choice in previously treated Asian patients with HER2-low unresectable/metastatic breast cancer: subgroup analysis of the DESTINY-Breast04 study

2024-6-17

Cost-effectiveness of adjuvant endocrine treatment with tamoxifen for male breast cancer

2024-6-15

Neoadjuvant talazoparib in patients with germline BRCA1/2 mutation-positive, early-stage triple-negative breast cancer: exploration of tumor BRCA mutational status

2024-6-13

Delayed breast reconstruction with autologous free flap after radiation therapy: vascular complications and aesthetic outcomes

2024-6-12

Validation of late recurrence prediction by gene expression profiles and clinicopathological factors in estrogen receptor-positive breast cancer

2024-6-11

Breast cancer epigenetics: current and evolving treatment

2024-6-11

Exosomal lncRNA SNHG12 promotes angiogenesis and breast cancer progression

2024-6-4

Comparison of water- vs. land-based exercise for improving functional capacity and quality of life in patients living with and beyond breast cancer (the AQUA-FiT study): a randomized controlled trial

2024-5-30

Contrast-enhanced mammography in the management of breast architectural distortions and avoidance of unnecessary biopsies

2024-5-29

A novel nomogram and survival analysis for different lymph node status in breast cancer based on the SEER database

2024-5-27

Assessing the effectiveness of high frequency repetitive transcranial magnetic stimulation for post-mastectomy pain in breast cancer patients: A randomized controlled trial

2024-5-26

A randomized trial of the impact of symptom monitoring using an electronic patient-reported outcome app on health-related quality of life in postmenopausal breast cancer patients receiving adjuvant endocrine therapy

2024-5-26

Antitumor effects of co-treatment of resveratrol with antitumor drugs in ER- and HER2-positive breast cancer cells are due to induction of apoptosis and modulation of estrogen receptor expression

2024-5-23

Mesenchymal-like immune-altered is the fourth robust triple-negative breast cancer molecular subtype

2024-5-22

Not all patients with premenopausal breast cancer will experience the negative effects of tamoxifen treatment on their bone mineral density

2024-5-18

Resilience’s impact on quality of life and post-traumatic growth in breast cancer patients during treatment

2024-5-17

Correction: The Japanese Breast Cancer Society Clinical Practice Guidelines for Breast Cancer, 2022 Edition: changes from the 2018 edition and general statements on breast cancer treatment

2024-5-12

Simultaneous integrated boost intensity-modulated radiotherapy post breast-conserving surgery: clinical efficacy, adverse effects, and cosmetic outcomes in breast cancer patients

2024-5-5

Real-world data of HER2-negative early breast cancer patients treated with anthracycline and/or taxane regimens in Japan

2024-4-29

Adverse effects of tamoxifen treatment on bone mineral density in premenopausal patients with breast cancer: a systematic review and meta-analysis

2024-4-27

Percutaneous ultrasound-guided cryoablation for early-stage primary breast cancer: a follow-up study in Japan

2024-4-27

Global untargeted and individual targeted plasma metabolomics of breast cancer recurrence modified by hormone receptors

2024-4-23

Perspectives for the clinical application of ctDNA analysis to breast cancer drug therapy

2024-4-23

Number of lines of previous chemotherapy regimen might affect the oucome of sacituzumab govitecan in metastatic triple-negative breast cancer patients

2024-4-22

Comparing survival outcomes between neoadjuvant and adjuvant chemotherapy within T2N1M0 stage hormone receptor-positive, HER2-negative breast cancer: a retrospective cohort study based on SEER database

2024-4-21